Portfolio
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2
IFF
FY2025 Q4
Улучшается
Отчётный звонок International Flavors & Fragrances, Inc.
Вывод Buzzberg
Food ingredients sale process officially launched, strong interest from strategics and sponsors.
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
Вывод Buzzberg Food ingredients sale process officially launched, strong interest from strategics and sponsors. IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent. Читать полный анализСвернуть анализ
IFF reported Q4 2025 results in line with expectations, showing modest revenue growth and strong EBITDA expansion. Management's guidance for 2026 is cautiously optimistic, expecting volume-led growth, but acknowledges macro uncertainties and the ongoing food ingredients divestiture. The company is actively reshaping its portfolio toward high-value, innovation-driven businesses (Taste, Scent, Health & Biosciences) while managing down debt and improving cash flow. Portfolio reshaping is a key theme: announced sale process for food ingredients, with strong interest from strategics and financial sponsors; also closing the sale of soy businesses to Bunge and completed divestitures of Pharma Solutions, Nitrocellulose, and Rene Laurent.
- FY2026 guidance is for comparable currency neutral sales growth of 1-4% and EBITDA growth of 3-8%, driven primarily by volume. Management expects pricing to be slightly down, mainly on commodity fragrance ingredients.
- The company is emphasizing cash flow generation and working capital discipline, introducing a new incentive metric for 2026, and expects meaningful cash flow improvement over 2025.
- Innovation is a core driver for future growth, particularly in areas like enzymes, natural ingredients, and biotechnology-enabled solutions like EnviroCaps and Super Carrot.
Выручка$2.589BФакт
EPS$0.80Факт
Валовая маржа34.38%Факт
Операционная маржа4.36%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Guidance
2026 sales guidance of 1-4% growth driven entirely by volume, pricing slightly down.
Demand
Health business expected to flatten in H1 and grow in H2 2026.
Показать ещё 3 тезиса
Margins
Incremental margins on volume are roughly 30-35%.
Cash Flow
Free cash flow improvement is a key priority for 2026, with new incentive metric.
Portfolio
Fragrance ingredients commodity portfolio under pressure, shifting to specialties.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $2.589B | Факт |
| EPS | $0.80 | Факт |
| Валовая маржа | 34.38% | Факт |
| Операционная маржа | 4.36% | Факт |
| Свободный денежный поток | $0.13B | Факт |
| Капзатраты | $0.188B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Капзатраты | FY2026 | 6% | 6% | Обозначен |
| Операционная маржа | FY2026 | $2.05B–$2.15B | $2.1B | Обозначен |
| Выручка | FY2026 | $10.5B–$10.8B | $10.65B | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed conviction in their strategic direction, portfolio optimization, and growth trajectory despite acknowledging macroeconomic challenges.
Инвестиции и мощности
CapEx is expected to be around 6% of sales in 2026, carefully managed and focused on highest return opportunities including capacity expansion, network optimization, and innovation to support long-term growth.
все упомянутые компании ниже: 1
Компаниис момента звонка
Партнёры
Партнёры
Eric Feerwald
IFF is divesting its soy businesses to Bunge, reflecting continued portfolio reshaping; likely part of broader strategic consolidation in agricultural processing.
Доказательства
“announced an agreement to sell our soy crush, concentrates, and lecithin businesses to Bungee, which we expect to happen by April”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
IFF expects full year 2026 pricing to be slightly down, primarily due to continued price competition and softness in commodity fragrance ingredients. The company is shifting toward higher-value specialty ingredients to mitigate this.
Доказательства
“We do expect pricing to be slightly down, which is primarily related to the commodity portion of our fragrance ingredients”
IFF has officially launched the sales process for its food ingredients business and has seen interest from strategics and financial sponsors. They expect to capture value, with proceeds used for share buybacks and debt paydown.
Доказательства
“following several months of extensive preparation by our team, we formally launched a disciplined and competitive sale process, and as of two weeks ago, are officially in the market.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 1. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.